HS Chapter 30
Pharmaceutical products
6 headings · 57 HS codes. Choose a 4-digit heading to see its tariff lines.
Recorded imports
Between December 2025 and May 2026, NBR recorded commercial imports worth BDT 27,821,063,021 (2,427,746 kg) under this chapter, across 42 of its 57 tariff lines. The remaining 15 recorded no commercial import in that window.
| Month | Lines with imports | Net weight | Assessable value |
|---|---|---|---|
| December 2025 | 32 | 360,665 kg | BDT 4,718,321,045 |
| January 2026 | 32 | 402,718 kg | BDT 7,125,785,835 |
| February 2026 | 34 | 351,689 kg | BDT 3,213,545,921 |
| March 2026 | 37 | 498,868 kg | BDT 2,771,106,379 |
| April 2026 | 34 | 419,885 kg | BDT 3,928,334,488 |
| May 2026 | 31 | 393,921 kg | BDT 6,063,969,353 |
The largest lines by assessable value in May 2026:
- 30024100 — Vaccines for human medicine — BDT 4,174,428,662
- 30024200 — Vaccines for veterinary medicine — BDT 545,816,141
- 30049099 — Other(excl.anti-malaria, anti-TB, anti-leprosy....and kidney dialysis solution — BDT 288,470,325
- 30043100 — Medicaments Containing Insulin, For Retail Sale — BDT 154,502,150
- 30021200 — Antisera and other blood fractions — BDT 136,761,627
Bonded imports. A further BDT 4,113,840 (2,781 kg) entered under the bonded-warehouse regime over the same months — duty-free inputs imported against an undertaking to re-export them. That is 0.0% of the total value imported under this chapter.
Import figures: NBR Import Statements (IM-4 commercial, IM-7 bonded), December 2025 – May 2026. Assessable value is the customs value on which duty is charged, not the retail or invoice price.